Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 1,226,671 shares, an increase of 826.1% from the January 29th total of 132,462 shares. Currently, 19.6% of the shares of the stock are sold short. Based on an average trading volume of 6,360,187 shares, the days-to-cover ratio is currently 0.2 days. Based on an average trading volume of 6,360,187 shares, the days-to-cover ratio is currently 0.2 days. Currently, 19.6% of the shares of the stock are sold short.

Hedge Funds Weigh In On Biorestorative Therapies

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC lifted its position in shares of Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares in the last quarter. DRW Securities LLC bought a new position in Biorestorative Therapies in the 4th quarter worth approximately $55,000. Finally, Citadel Advisors LLC acquired a new position in Biorestorative Therapies during the 3rd quarter worth $152,000. 69.38% of the stock is owned by institutional investors.

Biorestorative Therapies Stock Performance

Shares of BRTX stock opened at $0.23 on Thursday. Biorestorative Therapies has a 52 week low of $0.19 and a 52 week high of $2.28. The stock has a market capitalization of $2.04 million, a PE ratio of -0.15 and a beta of 0.39. The stock’s fifty day moving average is $0.94 and its 200-day moving average is $1.26.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.